ATE194348T1 - Verfahren zur herstellung von camptothecin und analogen camptothecinen - Google Patents
Verfahren zur herstellung von camptothecin und analogen camptothecinenInfo
- Publication number
- ATE194348T1 ATE194348T1 AT92903792T AT92903792T ATE194348T1 AT E194348 T1 ATE194348 T1 AT E194348T1 AT 92903792 T AT92903792 T AT 92903792T AT 92903792 T AT92903792 T AT 92903792T AT E194348 T1 ATE194348 T1 AT E194348T1
- Authority
- AT
- Austria
- Prior art keywords
- loweralkyl
- amino
- camptothecines
- analogue
- loweralkoxy
- Prior art date
Links
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
- 229940127093 camptothecin Drugs 0.000 title 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- -1 amino, hydroxy Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/632,970 US5162532A (en) | 1990-12-20 | 1990-12-20 | Intermediates and method of making camptothecin and camptothecin analogs |
| PCT/US1991/009598 WO1992011263A1 (en) | 1990-12-20 | 1991-12-18 | Method of making camptothecin and camptothecin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE194348T1 true ATE194348T1 (de) | 2000-07-15 |
Family
ID=24537745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92903792T ATE194348T1 (de) | 1990-12-20 | 1991-12-18 | Verfahren zur herstellung von camptothecin und analogen camptothecinen |
| AT99112300T ATE294182T1 (de) | 1990-12-20 | 1991-12-18 | Zwischenprodukte zur herstellung von camptothecin und analogen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99112300T ATE294182T1 (de) | 1990-12-20 | 1991-12-18 | Zwischenprodukte zur herstellung von camptothecin und analogen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5162532A (de) |
| EP (2) | EP0565621B1 (de) |
| JP (3) | JP3141069B2 (de) |
| AT (2) | ATE194348T1 (de) |
| CA (3) | CA2112351C (de) |
| DE (2) | DE69132292T2 (de) |
| DK (2) | DK0565621T3 (de) |
| ES (2) | ES2241211T3 (de) |
| GR (1) | GR3034146T3 (de) |
| WO (1) | WO1992011263A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552154A (en) | 1989-11-06 | 1996-09-03 | The Stehlin Foundation For Cancer Research | Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof |
| US5212317A (en) * | 1990-12-20 | 1993-05-18 | North Carolina State University | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US6080751A (en) * | 1992-01-14 | 2000-06-27 | The Stehlin Foundation For Cancer Research | Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof |
| US5459269A (en) * | 1992-06-18 | 1995-10-17 | North Carolina State University | 14-halo-camptothecins |
| US5428166A (en) * | 1992-06-18 | 1995-06-27 | North Carolina State University | Method of making asymmetric de ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5391745A (en) * | 1992-07-23 | 1995-02-21 | Sloan-Kettering Institute For Cancer Research | Methods of preparation of camptothecin analogs |
| US5446047A (en) * | 1992-07-23 | 1995-08-29 | Sloan-Kettering Institute For Cancer Research | Camptothecin analogues |
| US5405963A (en) * | 1993-06-10 | 1995-04-11 | Smithkline Beecham Corporation | Process for asymmetric total synthesis of camptothecin analogues |
| US5475108A (en) * | 1993-08-31 | 1995-12-12 | North Carolina State University | Camptothecin intermediates and method of making camptothecin and comptothecin analogs |
| US5395939A (en) * | 1993-11-30 | 1995-03-07 | North Carolina State University | Method of making asymmetric de ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| GB9402934D0 (en) * | 1994-02-16 | 1994-04-06 | Erba Carlo Spa | Camptothecin derivatives and process for their preparation |
| US5491237A (en) * | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| JPH0873461A (ja) * | 1994-09-06 | 1996-03-19 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体、その製造法および抗腫瘍剤 |
| WO1996011005A2 (en) * | 1994-10-06 | 1996-04-18 | Atlas Leon T | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases |
| US5496952A (en) * | 1995-02-07 | 1996-03-05 | North Carolina State University | Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5942386A (en) * | 1995-06-07 | 1999-08-24 | Thomas Jefferson University | Anti-fungal agents and methods of identifying and using the same |
| US6815546B2 (en) | 1995-06-21 | 2004-11-09 | Societe De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them |
| US6797715B1 (en) * | 1995-06-21 | 2004-09-28 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them |
| MX9710228A (es) * | 1995-06-21 | 1998-03-31 | Sod Conseils Rech Applic | Nuevos analogos de camptotecina, procedimientos de preparacion, su aplicacion como medicinas y las composiciones farmaceuticas que los comprenden. |
| WO1998004557A1 (en) * | 1996-07-30 | 1998-02-05 | Bionumerik Pharmaceuticals, Inc. | Novel process for preparing camptothecin |
| US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
| JP4094710B2 (ja) | 1997-11-06 | 2008-06-04 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| DE60136490D1 (de) * | 2000-11-09 | 2008-12-18 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| US7049322B2 (en) * | 2002-02-21 | 2006-05-23 | Supergen, Inc. | Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
| JP4861340B2 (ja) * | 2005-02-22 | 2012-01-25 | エフ．ホフマン−ラ ロシュ アーゲー | カンプトセシンサブユニットの新規の合成法 |
| RU2447889C2 (ru) * | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| JP2008081492A (ja) | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| CN101522609A (zh) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| EP2211854A4 (de) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp |
| US8329711B2 (en) | 2007-10-23 | 2012-12-11 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| KR20100102637A (ko) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료 |
| US8288396B2 (en) | 2009-02-25 | 2012-10-16 | Msdkk | Pyrimidopyrimidoindazole derivative |
| EP2403339B1 (de) | 2009-03-06 | 2017-01-18 | Merck Sharp & Dohme Corp. | Tumorkombinationstherapie mit einem akt-hemmer und anderen antumormitteln |
| CN104163797A (zh) * | 2014-05-14 | 2014-11-26 | 遵义医学院 | 一种4-羟基-1，2，3，4-四氢喹啉的合成方法 |
| BR112022017064A2 (pt) | 2020-02-25 | 2022-11-16 | Mediboston Inc | Derivados da camptotecina e seus conjugados |
| US12521444B2 (en) | 2021-02-25 | 2026-01-13 | Fortvita Biologics Limited | Anti-HER2 antibody-drug conjugates and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI80022C (fi) * | 1982-07-05 | 1990-04-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat. |
| US4894456A (en) * | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| GB8800502D0 (en) * | 1988-01-11 | 1988-02-10 | Cerestar Holding Bv | Method of adding borax/boric acid to mixing/reaction-zone |
| JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
-
1990
- 1990-12-20 US US07/632,970 patent/US5162532A/en not_active Expired - Lifetime
-
1991
- 1991-12-18 DK DK92903792T patent/DK0565621T3/da active
- 1991-12-18 AT AT92903792T patent/ATE194348T1/de not_active IP Right Cessation
- 1991-12-18 WO PCT/US1991/009598 patent/WO1992011263A1/en not_active Ceased
- 1991-12-18 CA CA002112351A patent/CA2112351C/en not_active Expired - Fee Related
- 1991-12-18 ES ES99112300T patent/ES2241211T3/es not_active Expired - Lifetime
- 1991-12-18 DE DE69132292T patent/DE69132292T2/de not_active Expired - Fee Related
- 1991-12-18 CA CA002214037A patent/CA2214037C/en not_active Expired - Fee Related
- 1991-12-18 EP EP92903792A patent/EP0565621B1/de not_active Expired - Lifetime
- 1991-12-18 CA CA002324848A patent/CA2324848C/en not_active Expired - Fee Related
- 1991-12-18 EP EP99112300A patent/EP0963988B1/de not_active Expired - Lifetime
- 1991-12-18 DE DE69133455T patent/DE69133455T2/de not_active Expired - Fee Related
- 1991-12-18 JP JP04503829A patent/JP3141069B2/ja not_active Expired - Fee Related
- 1991-12-18 ES ES92903792T patent/ES2147728T3/es not_active Expired - Lifetime
- 1991-12-18 AT AT99112300T patent/ATE294182T1/de not_active IP Right Cessation
- 1991-12-18 DK DK99112300T patent/DK0963988T3/da active
-
1993
- 1993-02-12 US US08/017,648 patent/US5321140A/en not_active Expired - Lifetime
-
2000
- 2000-07-25 JP JP2000224114A patent/JP3262781B2/ja not_active Expired - Fee Related
- 2000-07-25 JP JP2000224113A patent/JP3234828B2/ja not_active Expired - Fee Related
- 2000-08-08 GR GR20000401841T patent/GR3034146T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2112351C (en) | 1998-02-10 |
| ES2147728T3 (es) | 2000-10-01 |
| DK0565621T3 (da) | 2000-10-09 |
| JP2001064257A (ja) | 2001-03-13 |
| WO1992011263A1 (en) | 1992-07-09 |
| EP0963988A3 (de) | 2001-07-11 |
| DE69133455D1 (de) | 2005-06-02 |
| DK0963988T3 (da) | 2005-07-25 |
| JP3262781B2 (ja) | 2002-03-04 |
| EP0565621B1 (de) | 2000-07-05 |
| DE69133455T2 (de) | 2006-04-27 |
| JP2001055377A (ja) | 2001-02-27 |
| JP3234828B2 (ja) | 2001-12-04 |
| DE69132292D1 (de) | 2000-08-10 |
| HK1025565A1 (en) | 2000-11-17 |
| EP0963988B1 (de) | 2005-04-27 |
| EP0963988A2 (de) | 1999-12-15 |
| GR3034146T3 (en) | 2000-11-30 |
| CA2214037A1 (en) | 1992-07-09 |
| US5321140A (en) | 1994-06-14 |
| JPH06504062A (ja) | 1994-05-12 |
| EP0565621A1 (de) | 1993-10-20 |
| ATE294182T1 (de) | 2005-05-15 |
| CA2214037C (en) | 2001-11-27 |
| CA2324848C (en) | 2005-07-26 |
| CA2324848A1 (en) | 1992-07-09 |
| ES2241211T3 (es) | 2005-10-16 |
| CA2112351A1 (en) | 1992-07-09 |
| DE69132292T2 (de) | 2001-02-22 |
| EP0565621A4 (de) | 1995-08-09 |
| JP3141069B2 (ja) | 2001-03-05 |
| US5162532A (en) | 1992-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69132292D1 (de) | Verfahren zur herstellung von camptothecin und analogen camptothecinen | |
| DE69534029D1 (de) | Herstellung von Camptothecinderivaten durch intramolekulare Cyclisierung | |
| DK89595A (da) | Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril | |
| NO932870L (no) | Ny fremgangsmaate for fremstilling av 9-amino-6-demetyl-6-deoksyetracykliner | |
| DE59108707D1 (de) | Verfahren zur Herstellung von Oxetanonen | |
| ATE163012T1 (de) | N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel | |
| DE69621649D1 (de) | Verfahren zur herstellung von cefdinir | |
| DE3576952D1 (de) | Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten. | |
| ATE66913T1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
| DE69231815D1 (de) | Verfahren zur Herstellung von Cephalosporinen und Zwischenprodukte in diesem Verfahren | |
| DE69518164D1 (de) | Verfahren zur herstellung von n-(amidinophenyl pyrrolidin)-n'-beta-alanin-substituierten harnstoffen | |
| ATE150453T1 (de) | Verfahren zur herstellung von trans-piperidin-2,5-dicarboxylaten | |
| DE69529499D1 (de) | Stereoselektives Verfahren zur Herstellung von Dihydro-2,3-benzodiazepin-Derivaten | |
| ATE282594T1 (de) | Verfahren zur herstellung von (+)-trans-4-p- fluorophenyl-3-hydroxymethyl-1-methylpiperidin | |
| ATE163411T1 (de) | Verfahren zur herstellung von 2-substituierten 5- chlorimidazol-4-carbaldehyden | |
| DE69223156D1 (de) | Verfahren zur herstellung von enantiomer reinem imidazo (4,5,1-jk) (1,4)-benzodiazepin-2(1h)-thionen | |
| DE69126326D1 (de) | Verfahren und Zwischenprodukte zur Herstellung von anxiolytisch wirksamen Perhydro-1H-pyrido[1,2-a]pyrazinen | |
| ATE111093T1 (de) | Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten. | |
| DE50202096D1 (de) | Verfahren zur Herstellung von 5-Alkoxy-Oxazolen sowie von Pyridoxinen | |
| DK358486D0 (da) | Fremgangsmaade til fremstilling af 2-acyl-3,4-dialkoxyaniliner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |